Core Viewpoint - 180 Life Sciences Corp. (d/b/a ETHZilla) is focusing on increasing its Ethereum (ETH) holdings through a recent $156 million convertible notes offering, which is part of its broader ETH treasury strategy [1][2][6] Group 1: Financing and Strategy - The company has closed a $425 million private placement and subsequently sold approximately $156 million in senior secured convertible notes due 2028 [1][2] - Proceeds from the convertible notes will primarily be used to purchase more ETH and support the company's ETH treasury strategy [2][3] - The convertible notes will not accrue interest for the first six months and will have a 4% annual interest rate thereafter, maturing three years from the issuance date [2] Group 2: Company Operations and Future Plans - The company aims to rebrand as ETHZilla Corporation and establish itself as a leader in on-chain treasury management among public companies [6] - A significant portion of the company's operations will focus on becoming an ETH accumulation vehicle, designed to provide community access to the Ethereum network [7] - The company plans to implement a differentiated yield generation program in partnership with Electric Capital, aiming to outperform traditional ETH staking [7] Group 3: Legal and Advisory Support - Clear Street LLC acted as the financial advisor and exclusive placement agent for the convertible notes offering, while The Loev Law Firm, PC and Reed Smith LLP provided legal advice to the company [4]